Updated information on COVID-19 and Flu: Restricted visitation is now in effect
Category
Cancer
Sub Category
Breast
Study Name
NSABP FB-12: An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
Principal Investigator
Gordan Srkalovic
Study Information
https://clinicaltrials.gov/ct2/show/NCT03412643
Contact for Questions
Clinical Trials Office – 517.364.9400

Site view: at a glance